ISPOR’s Top 10 HEOR Trends – Healthcare Economist

These trends are summarized as Web page and in larger Report. Here are some key excerpts from their report:

1. real world evidence. “As RWE continues to gain significant attention in the healthcare sector, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the National Institute for Health and Care Excellence (NICE) and the Canadian Center for Medicines and Health Technologies, The agency within the Agency (CADTH) has recently published guidance on different aspects of the generation and use of RWE. Key topics are data quality, fitness for purpose, registration and external controls.”
2. drug pricing. “The discussion is driven by policies such as the US Inflation Reduction Act (IRA), under which US health insurance plans will negotiate with manufacturers on the prices of 10 high-cost drugs, and the EU Drugs Strategy, which proposes several Ways to improve accessibility and affordability”
3. AI. “In health economics, these machine learning (ML) algorithms can be used to view data in a variety of ways to help researchers and payers better understand the safety and effectiveness of treatments. ML algorithms can also be used to Build physician diagnostic tools that serve as quality checks on human work (e.g., a physician’s evaluation of radiology exams), or build apps that can be used to self-manage conditions (e.g., low back pain or schizophrenia).”
4. Promote innovation. “…Certain areas of medicine are in desperate need of innovation but are not receiving the necessary attention due to a lack of financial incentives for drug development. A prime example is the search for new treatments against drug-resistant bacteria, fungi and other pathogens.”
5. health equity. “The use of social determinants of health (SDoH) in HEOR is increasing… The U.S. Department of Health and Human Services (HHS) Office of Disease Prevention and Health Promotion recognizes SDoH as part of its Healthy People 2030 plan. HHS divides SDoH into 5 Areas: Economic stability, educational opportunity and quality, health care access and quality, neighborhood and built environment, and social and community environment.”
6. Accelerate drug approval. ” In 2022, 24 of the 37 Centers for Drug Evaluation and Research (or 65%) used one or more expedited procedures, such as fast track, breakthrough therapy, priority review, or accelerated approval… In the EU, of the 89 drugs approved by the European Medicines Agency in 2022, 5 are undergoing accelerated evaluation, 9 have received conditional marketing authorization, and 5 have been approved under special circumstances. “
7. value measurement. “Several efforts have been made to address these issues through QALY. ISPOR value spends include other important aspects of value, such as severity of illness, equity and hope value, as well as other personal and social considerations. 40 Broad risk The Adjusted Cost-Effectiveness (GRACE) approach incorporates risk aversion into people's risk aversion. Preferences, uncertainty about treatment outcomes, many elements of the flower of value, and others are all rolled into one economic indicator.”
8. Patient-centered. “…[FDA] Participated in a range of patient engagement initiatives, including the development of a series of 4 patient-centered methodological drug development guidance documents to step-by-step address how stakeholders collect and submit patient experience data and other relevant information from patients and caregivers to healthcare Product development and regulatory decisions. EUnetHTA recommends in its Guidelines for Patient and Healthcare Professional Engagement that joint clinical assessments planned to facilitate cross-border collaboration on European health technology assessment include meaningful participation of patients to reflect their views on coverage and reimbursement decisions.
9. precision medicine. “…In 2022, the U.S. Food and Drug Administration (FDA) approved 12 personalized medicines, accounting for approximately 34% of all newly approved therapeutic molecular entities. Over the past eight years, personalized medicines have accounted for at least four of the new drugs approved each year. One percent.”
10. public health. Factors such as infectious diseases, social unrest and economic downturns can affect health and are also noted in the ISPOR report.

read full report Learn more and learn about ISPOR's many initiatives on these 10 topics.